{
  "id": 7803087,
  "title": "Axsome Therapeutics at H.C. Wainwright conference: growth broadens",
  "url": "https://urgent.news/2026/09/16/axsome-therapeutics-at-h-c-wainwright-conference-growth-broadens",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T14:31:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/axsome-therapeutics-at-hc-wainwright-conference-growth-broadens-93CH-4904005"
  },
  "original_language": "en",
  "account": "On September 16, 2026, Axsome Therapeutics (AXSM) presented at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting the company's transition from a clinical-stage biotech to a commercial entity. Management emphasized strong sales momentum and a diverse neuroscience pipeline for future growth, noting three marketed products and 10 development areas spanning psychiatry and neurology. Q2 2024 revenue reached $218.4 million, a 46% increase from the previous year, primarily driven by Auvelity, which generated over $180 million. Auvelity is positioned as the first oral NMDA receptor antagonist and sigma-1 agonist for major depressive disorder and Alzheimer’s disease agitation. The company has $320 million in cash reserves and expects operating expenses to stabilize later in 2024. Management sees Auvelity as the main growth engine, with peak sales potential exceeding $8 billion, with the majority expected from major depressive disorder and Alzheimer’s disease agitation. Sunosi, a dopamine and norepinephrine reuptake inhibitor, generated $36 million in Q2 2024 and has potential for $300 million to $500 million in peak sales. SYMBRAVO, a monoclonal antibody for acute migraine, generated $2.3 million in Q2 2024 and is expected to grow. Axsome aims to file one new NDA annually through 2031, with several Phase III programs already underway.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "PTC Therapeutics at Wells Fargo conference: Sephiance drives growth plan",
        "url": "https://urgent.news/2026/09/16/ptc-therapeutics-at-wells-fargo-conference-sephiance-drives-growth",
        "published": "2026-09-16T01:42:10.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}